The case for & against
Bull & Bear analysis
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is an emerging player in the healthcare sector that specializes in innovative solutions for obstructive sleep apnea (OSA) through its proprietary oral appliances. The company has recently pivoted towards a medical service organization model following the strategic acquisition of the Sleep Center of Nevada (SCN). This acquisition positions Vivos to enhance its service delivery model and capitalize on the advancing demand for effective sleep disorder treatments. Vivos Therapeutics is recognized for its FDA-cleared products and aims to capture a significant portion of the expanding market for non-invasive OSA therapies.
Bull says
- ↑Q1 revenue +70% YoY to $5.1M driven by SCN acquisition
- ↑Gross margin improved to 60% under higher-margin service model
- ↑FDA-cleared oral appliances align with rising non-invasive OSA demand
- ↑Pediatric program targets ~$1M revenue per site at >60% margin
- ↑High dividend yield and strong liquidity with manageable leverage risk
Bear says
- ↓Q1 net loss widened to $7.8M; going-concern qualifier noted
- ↓Working-capital deficit of $13.1M requires additional financing
- ↓G&A expenses up 83% YoY to $9M due to SCN integration
- ↓Current debt of $8.3M strains cash flow and risks dilution
- ↓CPAP remains first-line for 95% of OSA patients, hindering uptake
- ↓Negative earnings yield, weak profitability, and high short interest
Earnings Call · Q2 2025 · Mgmt. Guidance
Transcript signals
Bull points
- In the second quarter of 2025, Vivos achieved a major milestone in our pivot of our sales, marketing, and distribution model to focus on sleep, center, provider-based alliances and acquisitions with our June 10, 2025 acquisition of the Sleep Center of Nevada.
- Importantly, we saw an immediate $500,000 uplift in sleep testing service revenue attributable to SCN. And that's just for the period from June 10th, which was the SCN closing, through the end of the quarter.
- We saw a $400,000 boost in sponsorship, seminar, and other service revenue as well.
Bear points
- For the second quarter of 2025, we saw a slight decrease in revenue, down about 6% to $3.8 million, compared to $4.1 million in the second quarter of 2024. The decline in revenue reflects additional expenses related to the transition and integration of our SCN into our operations.
- Cost of sales and operating expenses increased significantly, primarily due to our acquisition and integration of Sleep Center of Nevada. The closing of the transaction and integration of SCN led to higher quarter over quarter professional fees, personnel costs, and infrastructure expenses. The primary cause of this increase was approximately $1.8 million in costs associated with acquiring and integrating SCN, including professional fees of about $900,000, salaries and wages of approximately a half a million dollars, and infrastructure costs of approximately $300,000.
- Our operating loss widened to $4.9 million in second quarter and $8.8 million for the first half of 2025, reflecting these higher expenses and lower revenues during our strategic transition.